Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Sponsor
Fuda Cancer Hospital, Guangzhou
Study ID
NCT02857920
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Malignant Solid Tumour

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Bevacizumab — DRUG
    7.5 mg/kg, i.v, once every 3 weeks (continuous)
  • NK immunotherapy — BIOLOGICAL
    Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.

Study Details

The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

Key Dates

First listed
Aug 5, 2016
Start date
Aug 1, 2016
Status verified
Aug 2018
Primary completion
Aug 1, 2017
Completion
Aug 1, 2019

Study Design

Enrollment
45 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab and NK immunotherapy
    In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
  • Active Comparator: Bevacizumab
    In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Primary Outcome Measure

PFS [ Time Frame: 1 year ]

Related Studies